Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China Regulatory Shakeup: Top Regulator Out, Commissioner Reprimanded Amid Vaccine Scandal

Executive Summary

Amid aftermath of latest vaccine scandal, top officials including China’s drug reform flagbearer are forced to resign, sending shock waves across the industry.


Related Content

Nine Catalysts For China Biopharma In 2019
Eight For 8: Things You Need To Know About China Biopharma Regulation In 2018
A Shocking Shot: China's Latest Vaccine Forgery More Problematic Than Ever
Bigger, Bolder, SMAR: Decoding China's All-In-One Regulatory Agency
China Innovation Policy Reform Streamlines Trial Management
Foreign Drugs Welcome As China Reforms Progress: CFDA Commissioner
Mission: Ongoing! China Looks To Align With FDA In Landmark IND Push
Fast And Furious: Lessons From China FDA's Innovation Push
China Vaccine Scandal: Hundreds Demoted But Root Causes Remain
Asia Spotlight: Improve Quality Or You're Out, Says China FDA Commissioner





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts